A Trial of Artemether or Quinine in Children with Cerebral Malaria
Open Access
- 11 July 1996
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 335 (2), 69-75
- https://doi.org/10.1056/nejm199607113350201
Abstract
Cerebral malaria has a mortality rate of 10 to 30 percent despite treatment with parenteral quinine, a situation that may worsen with the spread of quinine resistance. Artemether is a new antimalarial agent that clears parasites from the circulation more rapidly than quinine, but its effect on mortality is unclear.Keywords
This publication has 13 references indexed in Scilit:
- Indicators of Life-Threatening Malaria in African ChildrenThe New England Journal of Medicine, 1995
- ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarctionThe Lancet, 1995
- Neurotoxicity in animals due to arteether and artemetherTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- Quinine in severe falciparum malaria: evidence of declining efficacy in ThailandTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- Rapid coma resolution with artemether in Malawian children with cerebral malariaThe Lancet, 1993
- QinghaosuThe Lancet, 1993
- The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1990
- Blood Glucose Levels in Malawian Children before and during the Administration of Intravenous Quinine for Severe falciparum MalariaThe New England Journal of Medicine, 1988
- HYPOGLYCAEMIA IN AFRICAN CHILDREN WITH SEVERE MALARIAThe Lancet, 1987
- Severe Hypoglycemia and Hyperinsulinemia in Falciparum MalariaThe New England Journal of Medicine, 1983